News & numbers


Step into the real world 94% 96%


Respondents that believe using RWE in R&D will become important or very important to their organisations by 2022.


70%


Those that expect RWD and RWE to have a greater impact on R&D in oncology,


as compared with other therapy areas.


Believe RWE will become very important to their C-suite by 2022.


>40%


Those that say there is a need for increased availability of high- quality and reliable RWD.


~30%


Respondents that attribute the heightened sense of importance of RWE within their organisations to


recent FDA guidance and statements encouraging life sciences companies to expand the use of RWE in R&D.


70%


Respondents that say a lack of research- grade data is hindering RWE efforts in R&D.


Using real-world evidence to enhance the R&D process


In 2016, real-world evidence received a boost with the passage of the 21st Century Cures Act.


Real-world data (RWD) is data relating to patient health status and/or the delivery of healthcare routinely collected from a variety of sources.


Real-world evidence (RWE) is the clinical evidence about the usage and potential benefi ts or risks of a medical product derived from analysis of RWD.


Source: US FDA


>80% 3/4


Companies surveyed that are entering into strategic partnerships to access new sources of RWD.


Respondents reported having a central analytics platform to manage and analyse RWD.


Source: Deloitte Clinical Trials Insight / www.worldpharmaceuticals.net 7


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45